Difference between revisions of "Tumour-infiltrating lymphocytes"
Jump to navigation
Jump to search
| (8 intermediate revisions by the same user not shown) | |||
| Line 11: | Line 11: | ||
|- | |- | ||
| [[Colorectal carcinoma]] | | [[Colorectal carcinoma]] | ||
| [[Microsatellite instability in colorectal cancer|microsatellite instability]]<ref name=pmid21114775>{{Cite journal | last1 = Iacopetta | first1 = B. | last2 = Grieu | first2 = F. | last3 = Amanuel | first3 = B. | title = Microsatellite instability in colorectal cancer. | journal = Asia Pac J Clin Oncol | volume = 6 | issue = 4 | pages = 260-9 | month = Dec | year = 2010 | doi = 10.1111/j.1743-7563.2010.01335.x | PMID = 21114775 }}</ref> | | [[Intratumoural lymphocytic response in colorectal carcinoma|TILs in CRC]] are associated with [[Microsatellite instability in colorectal cancer|microsatellite instability]]<ref name=pmid21114775>{{Cite journal | last1 = Iacopetta | first1 = B. | last2 = Grieu | first2 = F. | last3 = Amanuel | first3 = B. | title = Microsatellite instability in colorectal cancer. | journal = Asia Pac J Clin Oncol | volume = 6 | issue = 4 | pages = 260-9 | month = Dec | year = 2010 | doi = 10.1111/j.1743-7563.2010.01335.x | PMID = 21114775 }}</ref> | ||
|- | |- | ||
| [[Malignant melanoma]] | | [[Malignant melanoma]] | ||
| | | TILs better survival<ref>{{Cite journal | last1 = Lee | first1 = N. | last2 = Zakka | first2 = LR. | last3 = Mihm | first3 = MC. | last4 = Schatton | first4 = T. | title = Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. | journal = Pathology | volume = 48 | issue = 2 | pages = 177-87 | month = Feb | year = 2016 | doi = 10.1016/j.pathol.2015.12.006 | PMID = 27020390 }}</ref> | ||
|- | |- | ||
|[[Non-small cell lung cancer]] | |[[Non-small cell lung cancer]] | ||
| associated with anti-[[PD-L1]] response<ref name=pmid26970723>{{Cite journal | last1 = Fehrenbacher | first1 = L. | last2 = Spira | first2 = A. | last3 = Ballinger | first3 = M. | last4 = Kowanetz | first4 = M. | last5 = Vansteenkiste | first5 = J. | last6 = Mazieres | first6 = J. | last7 = Park | first7 = K. | last8 = Smith | first8 = D. | last9 = Artal-Cortes | first9 = A. | title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. | journal = Lancet | volume = | issue = | pages = | month = Mar | year = 2016 | doi = 10.1016/S0140-6736(16)00587-0 | PMID = 26970723 }}</ref> | | TILs associated with anti-[[PD-L1]] response<ref name=pmid26970723>{{Cite journal | last1 = Fehrenbacher | first1 = L. | last2 = Spira | first2 = A. | last3 = Ballinger | first3 = M. | last4 = Kowanetz | first4 = M. | last5 = Vansteenkiste | first5 = J. | last6 = Mazieres | first6 = J. | last7 = Park | first7 = K. | last8 = Smith | first8 = D. | last9 = Artal-Cortes | first9 = A. | title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. | journal = Lancet | volume = | issue = | pages = | month = Mar | year = 2016 | doi = 10.1016/S0140-6736(16)00587-0 | PMID = 26970723 }}</ref> | ||
|- | |- | ||
| [[Ovarian serous carcinoma]] | | [[Ovarian serous carcinoma]] | ||
| good prognosis<ref name=pmid26972336>{{Cite journal | last1 = Webb | first1 = JR. | last2 = Milne | first2 = K. | last3 = Kroeger | first3 = DR. | last4 = Nelson | first4 = BH. | title = PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. | journal = Gynecol Oncol | volume = 141 | issue = 2 | pages = 293-302 | month = May | year = 2016 | doi = 10.1016/j.ygyno.2016.03.008 | PMID = 26972336 }}</ref> | | TILs associated with good prognosis<ref name=pmid26972336>{{Cite journal | last1 = Webb | first1 = JR. | last2 = Milne | first2 = K. | last3 = Kroeger | first3 = DR. | last4 = Nelson | first4 = BH. | title = PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. | journal = Gynecol Oncol | volume = 141 | issue = 2 | pages = 293-302 | month = May | year = 2016 | doi = 10.1016/j.ygyno.2016.03.008 | PMID = 26972336 }}</ref> | ||
|- | |- | ||
|} | |} | ||
==Tumours with abundant lymphocytes as a component== | |||
*[[Nasopharyngeal carcinoma]]. | |||
*[[Lymphoepithelioma-like carcinoma]]. | |||
*[[Thymoma]]. | |||
*[[Follicular dendritic cell sarcoma]]. | |||
*[[Seminoma]]. | |||
*Others. | |||
==See also== | ==See also== | ||
*[[PD-L1]]. | *[[PD-L1]]. | ||
*[[Intratumoural lymphocytic response in colorectal carcinoma]]. | |||
*[[Peritumoural lymphocytic response]] (Crohn's like reaction). | |||
*[[Intraepithelial lymphocytes]]. | |||
==References== | ==References== | ||
Latest revision as of 16:05, 25 June 2021
Tumour-infiltrating lymphocytes, abbreviated TILs, is the presence of many lymphoctyes between tumour cells.
Tumour-infiltrating lymphocytes. H&E stain.
TILs in the context of colorectal carcinoma are dealt with in intratumoural lymphocytic response in colorectal carcinoma.
General
Common finding in a large number of tumours:
| Tumour | Association |
|---|---|
| Colorectal carcinoma | TILs in CRC are associated with microsatellite instability[1] |
| Malignant melanoma | TILs better survival[2] |
| Non-small cell lung cancer | TILs associated with anti-PD-L1 response[3] |
| Ovarian serous carcinoma | TILs associated with good prognosis[4] |
Tumours with abundant lymphocytes as a component
See also
- PD-L1.
- Intratumoural lymphocytic response in colorectal carcinoma.
- Peritumoural lymphocytic response (Crohn's like reaction).
- Intraepithelial lymphocytes.
References
- ↑ Iacopetta, B.; Grieu, F.; Amanuel, B. (Dec 2010). "Microsatellite instability in colorectal cancer.". Asia Pac J Clin Oncol 6 (4): 260-9. doi:10.1111/j.1743-7563.2010.01335.x. PMID 21114775.
- ↑ Lee, N.; Zakka, LR.; Mihm, MC.; Schatton, T. (Feb 2016). "Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.". Pathology 48 (2): 177-87. doi:10.1016/j.pathol.2015.12.006. PMID 27020390.
- ↑ Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D. et al. (Mar 2016). "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.". Lancet. doi:10.1016/S0140-6736(16)00587-0. PMID 26970723.
- ↑ Webb, JR.; Milne, K.; Kroeger, DR.; Nelson, BH. (May 2016). "PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.". Gynecol Oncol 141 (2): 293-302. doi:10.1016/j.ygyno.2016.03.008. PMID 26972336.